# Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer

> **NCT07273396** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Seoul National University Hospital** · enrollment: 53 (estimated)

## Conditions studied

- Ovarian Neoplasms
- Peritoneal Neoplasms

## Interventions

- **DRUG:** Pressurized intraperitoneal aerosol chemotherapy (PIPAC) using paclitaxel

## Key facts

- **NCT ID:** NCT07273396
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2030-04-30
- **Final completion:** 2030-08-31
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2025-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07273396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07273396, "Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07273396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*